Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Sinisa Bjelic"'
Autor:
Scott J. Garforth, Dick J Sjöström, Ana I. Teixeira, Camilla Mohlin, Sinisa Bjelic, Elena Ambrosetti
Publikováno v:
The FEBS Journal. 289:2935-2947
Human transferrin receptor 1 (TfR) is necessary for delivery of the iron carrier protein transferrin into cells and can be utilized for targeted delivery across cellular membranes. Binding of transferrin to the receptor is regulated by hereditary hem
Publikováno v:
Protein Science. 31
Diseases with readily available therapies may eventually prevail against the specific treatment by the acquisition of resistance. The constitutively active Abl1 tyrosine kinase known to cause chronic myeloid leukemia is an example, where patients may
Publikováno v:
Proteins
Machupo virus, known to cause hemorrhagic fevers, enters human cells via binding with its envelope glycoprotein to transferrin receptor 1 (TfR). Similarly, the receptor interactions have been explored in biotechnological applications as a molecular s
Autor:
Ran Friedman, Sinisa Bjelic
Publikováno v:
Israel Journal of Chemistry. 60:667-680
Protein kinases are enzymes with partially overlapping specificities, many of which are important clinical targets. In this article, we give some background on protein kinases and discuss in more d ...
Publikováno v:
Biochimica et Biophysica Acta (BBA) - General Subjects. 1863:732-741
Background Abl1 is a protein tyrosine kinase whose aberrant activation due to mutations is the culprit of several cancers, most notably chronic myeloid leukaemia. Several Abl1 inhibitors are used as anti-cancer drugs. Unfortunately, drug resistance l
Publikováno v:
Proteins: Structure, Function, and Bioinformatics
Supply of iron into human cells is achieved by iron carrier protein transferrin and its receptor that upon complex formation get internalized by endocytosis. Similarly, the iron needs to be delivered into the brain, and necessitates the transport acr
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19230 (2011)
The Rosetta de novo enzyme design protocol has been used to design enzyme catalysts for a variety of chemical reactions, and in principle can be applied to any arbitrary chemical reaction of interest. The process has four stages: 1) choice of a catal
Externí odkaz:
https://doaj.org/article/baa6d1863b6c44c884295fed67ad6eaf
Publikováno v:
The FEBS journalReferences. 287(15)
FMS-like tyrosine kinase 3 (FLT3) has been found to be mutated in ~ 30% of acute myeloid leukaemia patients. Small-molecule inhibitors targeting FLT3 that are currently approved or still undergoing clinical trials are subject to drug resistance due t
Autor:
Robert J. Floor, Dick B. Janssen, Sinisa Bjelic, Siewert J. Marrink, David Baker, Hein J. Wijma
Publikováno v:
Angewandte Chemie-International Edition, 54(12), 3726-3730. WILEY-V C H VERLAG GMBH
Computational enzyme design holds great promise for providing new biocatalysts for synthetic chemistry. A strategy to design small mutant libraries of complementary enantioselective epoxide hydrolase variants for the production of highly enantioenric
Autor:
Jeffery W. Kelly, Yun Lei Tan, David Baker, Gira Bhabha, Xin Zhang, Sinisa Bjelic, Yakov Kipnis, Damian C. Ekiert, Yu Liu
Publikováno v:
Journal of the American Chemical Society
Enzyme-based tags attached to a protein-of-interest (POI) that react with a small molecule, rendering the conjugate fluorescent, are very useful for studying the POI in living cells. These tags are typically based on endogenous enzymes, so protein en